Table 1 Population characteristics, by receipt of chemotherapy
From: Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019
Among those receiving chemotherapy | ||||
|---|---|---|---|---|
Overall | Participants who received chemotherapy (n, %) | Received trastuzumab and/or pertuzumab (n, %) | Did not receive trastuzumab and/or pertuzumab (n, %) | |
TOTAL | 33,670 | 13,089 (39%) | 3,548 (27%) | 9,541 (73%) |
Characteristic | ||||
Age at diagnosis (years) | ||||
18–39 | 1,509 (4.5%) | 1,194 (9.1%) | 365 (10.3%) | 829 (8.7%) |
40–49 | 5,283 (15.7%) | 3,230 (24.7%) | 802 (22.6%) | 2,428 (25.4%) |
50–64 | 13,656 (40.6%) | 6,064 (46.3%) | 1,619 (45.6%) | 4,445 (46.6%) |
65–79 | 10,568 (31.4%) | 2,516 (19.2%) | 715 (20.2%) | 1,801 (18.9%) |
80+ | 2,654 (7.9%) | 85 (0.6%) | 47 (1.3%) | 38 (0.4%) |
Race | ||||
White | 25,130 (74.6%) | 9,313 (71.2%) | 2,406 (67.8%) | 6,907 (72.4%) |
Black or African American | 2,459 (7.3%) | 1,106 (8.4%) | 261 (7.4%) | 845 (8.9%) |
Asian | 5,544 (16.5%) | 2,430 (18.6%) | 819 (23.1%) | 1,611 (16.9%) |
American Indian or Alaskan Native | 136 (0.4%) | 50 (0.4%) | 11 (0.3%) | 39 (0.4%) |
Native Hawaiian or Other Pacific Islander | 240 (0.7%) | 120 (0.9%) | 31 (0.9%) | 89 (0.9%) |
More than once race | 55 (0.2%) | 21 (0.2%) | 9 (0.3%) | 12 (0.1%) |
Unknown/missing | 106 (0.3%) | 49 (0.4%) | 11 (0.3%) | 38 (0.4%) |
Ethnicity | ||||
Not Hispanic | 29,341 (87.1%) | 11,059 (84.5%) | 3,037 (85.6%) | 8,022 (84.1%) |
Hispanic | 4,328 (12.9%) | 2,030 (15.5%) | 511 (14.4%) | 1,519 (15.9%) |
Year of diagnosis | ||||
2006–2010 | 11,056 (32.8%) | 4,566 (34.9%) | 974 (27.5%) | 3,592 (37.6%) |
2011–2015 | 12,482 (37.1%) | 4,816 (36.8%) | 1,329 (37.5%) | 3,487 (36.5%) |
2016–2019 | 10,132 (30.1%) | 3,707 (28.3%) | 1,245 (35.1%) | 2,462 (25.8%) |
AJCC Stagea | ||||
Stage I | 20,199 (60.0%) | 4,223 (32.3%) | 1,445 (40.7%) | 2,778 (29.1%) |
Stage II | 11,456 (34.0%) | 7,170 (54.8%) | 1,733 (48.8%) | 5,437 (57.0%) |
Stage IIIA | 2,015 (6.0%) | 1,696 (13.0%) | 370 (10.4%) | 1,326 (13.9%) |
Tumor subtype | ||||
Triple negative | 3,523 (10.5%) | 2,555 (19.5%) | 25 (0.7%) | 2,530 (26.5%) |
Hormone receptor +/HER2 - | 24,994 (74.2%) | 6,955 (53.1%) | 123 (3.5%) | 6,832 (71.6%) |
Hormone receptor +/HER2 + | 3,166 (9.4%) | 2,424 (18.5%) | 2,344 (66.1%) | 80 (0.8%) |
Hormone receptor -/HER2 + | 1,388 (4.1%) | 1,067 (8.2%) | 1,039 (29.3%) | 28 (0.3%) |
Unknown/not tested | 599 (1.8%) | 88 (0.7%) | 17 (0.5%) | 71 (0.7%) |